Asciminib
Asciminib is a pharmaceutical drug with 25 clinical trials. Currently 14 active trials ongoing. Historical success rate of 62.5%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
9
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
62.5%
5 of 8 finished
37.5%
3 ended early
14
trials recruiting
25
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia
Asciminib With or Without Sildenafil for Brain Tumors
Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
Clinical Trials (25)
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia
Asciminib With or Without Sildenafil for Brain Tumors
Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
Asciminib RMP Study
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor
RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)
Managed Access Programs for ABL001, Asciminib
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 25